A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group
- PMID: 7766740
- DOI: 10.1111/j.1365-2036.1995.tb00347.x
A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group
Abstract
Background: Lansoprazole is a new proton pump inhibitor which produces prolonged decrease of gastric acidity. The aim of this study was to compare lansoprazole to a standard dose of ranitidine in the treatment of patients with reflux oesophagitis.
Methods: Two hundred and forty-seven patients with erosive oesophagitis were randomly assigned to 8 weeks of treatment with either 30 mg lansoprazole once daily or 150 mg ranitidine twice daily.
Results: Two hundred and forty-two patients were included in the analysis. Lansoprazole (30 mg) daily, healed oesophagitis in 92.1% of patients after 8 weeks of treatment. This was significantly superior to 150 mg ranitidine b.d.s. which healed oesophagitis in 69.9% of patients (P < 0.001). Relief of reflux symptoms was superior with lansoprazole to that with ranitidine. Both lansoprazole and ranitidine were well tolerated with no serious drug-related adverse events noted.
Conclusion: Lansoprazole, 30 mg once daily, is highly effective and safe in the short-term treatment of erosive oesophagitis.
Similar articles
-
Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. The Dutch Lansoprazole Study Group.Aliment Pharmacol Ther. 1999 Dec;13(12):1611-20. doi: 10.1046/j.1365-2036.1999.00656.x. Aliment Pharmacol Ther. 1999. PMID: 10594396 Clinical Trial.
-
Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group.Aliment Pharmacol Ther. 1995 Apr;9(2):145-51. doi: 10.1111/j.1365-2036.1995.tb00363.x. Aliment Pharmacol Ther. 1995. PMID: 7605854 Clinical Trial.
-
Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.Am J Gastroenterol. 1997 Mar;92(3):429-37. Am J Gastroenterol. 1997. PMID: 9068463 Clinical Trial.
-
Lansoprazole in the treatment of reflux oesophagitis: a survey of clinical studies.Aliment Pharmacol Ther. 1993;7 Suppl 1:34-6, discussion 61-6. doi: 10.1111/j.1365-2036.1993.tb00586.x. Aliment Pharmacol Ther. 1993. PMID: 8490077 Review.
-
Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses.Expert Opin Pharmacother. 2001 Oct;2(10):1663-70. doi: 10.1517/14656566.2.10.1663. Expert Opin Pharmacother. 2001. PMID: 11825309 Review.
Cited by
-
Long-term comparison of antireflux surgery versus conservative therapy for reflux esophagitis.Ann Surg. 1997 Mar;225(3):295-9. doi: 10.1097/00000658-199703000-00009. Ann Surg. 1997. PMID: 9060586 Free PMC article. Clinical Trial.
-
Fewer acute respiratory infection episodes among patients receiving treatment for gastroesophageal reflux disease.PLoS One. 2017 Feb 21;12(2):e0172436. doi: 10.1371/journal.pone.0172436. eCollection 2017. PLoS One. 2017. PMID: 28222168 Free PMC article.
-
Esomeprazole tablet vs omeprazole capsule in treating erosive esophagitis.World J Gastroenterol. 2005 May 28;11(20):3112-7. doi: 10.3748/wjg.v11.i20.3112. World J Gastroenterol. 2005. PMID: 15918199 Free PMC article. Clinical Trial.
-
Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis.World J Gastroenterol. 2005 Jul 14;11(26):4067-77. doi: 10.3748/wjg.v11.i26.4067. World J Gastroenterol. 2005. PMID: 15996033 Free PMC article.
-
Efficacy of DA-5204 (Stillen 2X) for patients with gastroesophageal reflux disease: A randomized, double-blind, placebo-controlled pilot study.Medicine (Baltimore). 2020 Oct 30;99(44):e22729. doi: 10.1097/MD.0000000000022729. Medicine (Baltimore). 2020. PMID: 33126310 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources